Apogee Therapeutics, Inc. (APGE) Stock Price & Analysis

Apogee Therapeutics, Inc. (APGE) rose 0.00% to USD 135.07 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.

APGE last closed at USD 135.07; the session ranged USD 135.06–135.09 on volume of 0 shares. Market capitalization is —, with a 52-week range of USD 35.39–135.09 (NGM). Source: Nexqual, September 8, 2026 at 04:59 UTC.

Key Statistics (as of September 8, 2026 at 04:59 UTC)

Technical Analysis (APGE)

Nexqual's technical model rates APGE "BUY" based on 5 bullish and 1 bearish signals across 93 daily candles, as of September 8, 2026 at 04:59 UTC.

From Apogee Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe our approach will 10 Table of Contents   enable us to develop a portfolio of therapies that are differentiated compared to the currently available standards of care and address unmet medical needs for I&I indications, including the potential for improved dosing and/or efficacy.
• Our Approach Our goal is to discover and develop new therapies for a range of I&I indications.

Partnerships

• Our Collaboration, License and Services Agreements Paragon Option Agreements In February 2022, we entered into an antibody discovery and option agreement with Paragon, which was subsequently amended in November 2022 (as amended, the "2022 Option Agreement").
• In November 2023, we entered into an additional antibody discovery and option agreement with Paragon (the "2023 Option Agreement" and together with the 2022 Option Agreement, collectively, the "Option Agreements").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.